Advanced Filter

Filter by Group

Filter by Market Availability

Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Matched Name: … Osimertinib
Matched Description: … Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ... Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance ... prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during …
Matched Salts name: … osimertinib mesylate …
Displaying 1 drug